Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in <i>EGFR</i>-Mutant Lung Cancer

Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both EGFR-activating and EGFR inhibitor-resistant T790M mutations more potently than wild-type EGFR. Although this class of mutant-selective EGFR inhibitors is effective clinically in lung cancer patients harboring...

Full description

Saved in:
Bibliographic Details
Main Authors: Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal Rosen, Nathanael S. Gray, Kwok‐Kin Wong, Pasi A. Jänne
Format: Artigo
Language:English
Published: 2015
Online Access:https://doi.org/10.1158/2159-8290.cd-15-0063
https://cancerdiscovery.aacrjournals.org/content/candisc/5/9/960.full.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1158/2159-8290.cd-15-0063
https://cancerdiscovery.aacrjournals.org/content/candisc/5/9/960.full.pdf

Similar Items